SCY 078

Drug Profile

SCY 078

Alternative Names: MK-3118; SCY-078

Latest Information Update: 06 Mar 2017

Price : $50

At a glance

  • Originator Merck & Co; SCYNEXIS
  • Class Antifungals; Glycosides; Triterpenes
  • Mechanism of Action Beta-1,3-D glucan synthetase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Aspergillosis; Candidiasis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Aspergillosis; Candidiasis
  • New Molecular Entity No

Highest Development Phases

  • Phase II Candidiasis; Vulvovaginal candidiasis
  • Preclinical Aspergillosis

Most Recent Events

  • 02 Mar 2017 The US FDA requests SCYNEXIS to hold the initiation of any new clinical studies of intravenous formulation of SCY 078 following a review of a phase I trial in Healthy volunteers
  • 02 Mar 2017 Scynexis plans a phase III trial for invasive and mucocutaneous Candidiasis in USA (PO) (NCT03059992)
  • 25 Oct 2016 SCYNEXIS completes two drug-drug interaction clinical studies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top